November 1, 2006 -- The action in the IPO market for biomedical offerings has been heavy during September/October, with an unusually high number of biomedical companies scheduling their IPOs. In all, 13 biomedical companies decided that the fall of 2006 was the time to make the transition into public companies. Prices were uniformly weak, a constant theme this year. But six companies failed to price at all. We provide a list and a snapshot at the four biotech/pharma companies that completed their IPOs...
